Bankwell Financial Group, Inc. Announces Date of Second Quarter Earnings Conference Call
The audio webcast link, along with the corresponding presentation slides, will be available on the Company's Investor Relations site ( https://investor.mybankwell.com/news-market-data/event-calendar/default.aspx) prior to the beginning of the webcast. The webcast will also be archived on the Company's website for twelve months and can be accessed at any time during this period.
About Bankwell Financial Group, Inc.
Bankwell Financial Group, Inc. is the holding company for Bankwell Bank ("Bankwell"), a full-service commercial bank headquartered in New Canaan, CT. Bankwell offers its customers unmatched accessibility, expertise, and responsiveness through a range of commercial financing products including working capital lines of credit, SBA loans, acquisition loans, and commercial mortgages as well as treasury management and deposit services. More about Bankwell can be found at www.mybankwell.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 minutes ago
- Globe and Mail
ER+/ HER2-VE Breast Cancer Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'ER positive, HER2 negative Breast Cancer Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in ER positive, HER2 negative Breast Cancer pipeline landscape. It covers the ER+/ HER2 -ve Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ER+/ HER2 -ve Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive ER+/ HER2 -ve Breast Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report In August 2025, Yale University announced a phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Patients with ER+ breast cancer anatomic stage IIB or III at diagnosis who are at least five years from diagnosis and have completed intended course of adjuvant endocrine therapy and are currently off endocrine therapy will be screened with ctDNA testing. In July 2025, Atossa Therapeutics Inc. announced a study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment. The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. Promising ER+/ HER2 -ve Breast Cancer Therapies such as Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. Discover how the ER+/ HER2 -ve Breast Cancer treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ ER+/ HER2 -ve Breast Cancer Clinical Trials and Studies Camizestrant: AstraZeneca Camizestrant, is a next-generation oral selective estrogen receptor degrader (SERD), as a promising treatment for ER-positive, HER2-negative breast cancer. This drug, developed by AstraZeneca, and has shown significant potential in improving progression-free survival (PFS) compared to the standard treatment with fulvestrant, which has been the mainstay therapy for almost two decades. Camizestrant has demonstrated significant efficacy in clinical trials, particularly the SERENA-2 phase II trial. In this study, camizestrant was compared to fulvestrant, a well-established treatment. Patients receiving camizestrant showed improved progression-free survival (PFS) at doses of 75 mg and 150 mg, with median PFS of 7.2 and 9.2 months, respectively, compared to 3.7 months for those on fulvestrant. This trial also highlighted camizestrant's ability to reduce ESR1-mutant circulating tumor DNA, indicating a strong efficacy in combatting endocrine-resistant tumors. Safety profiles from these studies indicate that camizestrant is generally well-tolerated, with manageable side effects such as fatigue, anemia, and mild visual disturbances. The favorable balance between efficacy and safety has supported the advancement of camizestrant into further phase III trials, like SERENA-4 and SERENA-6, which are exploring its use in combination with CDK4/6 inhibitors for broader clinical application. Currently, the drug is in Phase III stage of its development for the treatment of HER2-negative breast cancer. (Z)-endoxifen: Atossa Therapeutics, Inc. (Z)-endoxifen is the most active metabolite of the FDA approved Selective Estrogen Receptor Modulator (SERM), tamoxifen. Studies have demonstrated that the therapeutic effects of tamoxifen are driven in a concentration-dependent manner by (Z)-endoxifen. In addition to its potent anti-estrogen effects, (Z)-endoxifen at higher concentrations has been shown to target PKCβ1, a known oncogenic protein. (Z)-endoxifen also appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with tamoxifen. Atossa is developing a proprietary oral formulation of (Z)-endoxifen that does not require liver metabolism to achieve therapeutic concentrations and is encapsulated to bypass the stomach as acidic conditions in the stomach convert a greater proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa's (Z)-endoxifen has been shown to be well tolerated in Phase I studies and in a small Phase II study of women with breast cancer. Currently, the drug is in Phase II stage of its development for the treatment of ER-positive, HER2-negative breast cancer. AC699 is a potent and selective orally bioavailable, chimeric degrader of estrogen receptor (ER) α, and offers a potential new breast cancer treatment option based on a differentiated mechanism of action as compared to fulvestrant and novel SERDs with deeper ERα degradation as demonstrated in preclinical studies. AC699 is currently being evaluated in an ongoing Phase I clinical study as a single agent for the treatment of ER-positive / HER2-negative locally advanced or metastatic breast cancer. The primary objectives are to evaluate the safety and tolerability of AC699. Secondary and exploratory objectives include pharmacokinetics, preliminary efficacy and pharmacodynamic evaluation. The study uses a 3+3 dose-escalation design, with once-daily oral dosing of AC699 at 100, 200, 300, 400, and 600 mg. The ER+/ HER2 -ve Breast Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ER+/ HER2 -ve Breast Cancer Treatment. ER+/ HER2 -ve Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market. Get a detailed analysis of the latest innovations in the ER+/ HER2 -ve Breast Cancer pipeline. Explore DelveInsight's expert-driven report today! @ ER+/ HER2 -ve Breast Cancer Unmet Needs ER+/ HER2 -ve Breast Cancer Companies AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming ER+/ HER2 -ve Breast Cancer Therapies and key developments @ ER+/ HER2 -ve Breast Cancer Market Drivers and Barriers, and Future Perspectives Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report Coverage- Global ER+/ HER2 -ve Breast Cancer Companies- AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, VelosBio Inc, Merus N.V., Pfizer, Olema Pharmaceuticals, Inc., Eli Lilly and Company, Novartis Pharmaceuticals, Hoffmann-La Roche, Ellipses Pharma, BeiGene and others. ER+/ HER2 -ve Breast Cancer Therapies- Entinostat, Aromatase Inhibitor (AI) Therapy, cetuximab, cisplatin, Palbociclib 125Mg Tab and others. ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in ER+/ HER2 -ve Breast Cancer drug development? Find out in DelveInsight's exclusive pipeline Report—access it now! @ ER+/ HER2 -ve Breast Cancer Emerging Drugs and Major Companies Table of Content Introduction Executive Summary ER+/ HER2-VE Breast Cancer: Overview Pipeline Therapeutics Therapeutic Assessment ER positive, HER2 negative Breast Cancer– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Camizestrant: AstraZeneca Drug profiles in the detailed report….. Mid Stage Products (Phase II) (Z)-endoxifen: Atossa Therapeutics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) AC699: Accutar Biotechnology Inc Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products ER+/ HER2-VE Breast Cancer Key Companies ER+/ HER2-VE Breast Cancer Key Products ER+/ HER2-VE Breast Cancer- Unmet Needs ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion ER+/ HER2-VE Breast Cancer Analyst Views ER+/ HER2-VE Breast Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
33 minutes ago
- Globe and Mail
ESAB (ESAB) Q2 Revenue Jumps 6%
Key Points Revenue (GAAP) exceeded expectations in Q2 2025, reaching $715.6 million, driven by acquisitions, compared to the estimated $674.5 million. Core adjusted EBITDA margin (non-GAAP) reached a record 20.4% in Q2 2025, reflecting ongoing margin improvement despite soft organic sales, particularly in the Americas. Full-year guidance was raised, with management now forecasts total core net sales growth of 1.5–3.5% for full year 2025 and higher targets for core adjusted EBITDA and core adjusted EPS for FY2025. These 10 stocks could mint the next wave of millionaires › ESAB (NYSE:ESAB), a leading global provider of fabrication technology and gas control solutions, reported Q2 2025 results on August 6, 2025. The most notable headline: GAAP revenue for Q2 2025 was $715.6 million, Q2 2025 GAAP revenue of $716 million exceeded analysts' estimates by $41.48 million, or 6.15%, while non-GAAP EPS of $1.36 matched consensus, while core adjusted earnings per share (non-GAAP) for Q2 2025 was $1.36, matching expectations. Management further raised its full-year 2025 guidance for core adjusted EBITDA and core adjusted EPS, boosted by contributions from recent acquisitions and robust business in EMEA (Europe, Middle East, Africa) and Asia-Pacific. Despite these positives, underlying organic growth was subdued in Q1 2025 and volumes in the Americas segment declined, offset only partly by price increases and product mix improvements. The period highlighted successful execution on margin expansion and strategic M&A, supporting a solid quarter for the company. Metric Q2 2025 Q2 Estimate Q2 2024 Y/Y Change EPS (Non-GAAP) $1.36 $1.36 $1.32 3.0% Revenue (GAAP) $715.6 million $674.5 million $707.1 million 1.2% Core Adjusted EBITDA Margin 20.4% 20.1% 0.3 pp Adjusted Free Cash Flow (Non-GAAP) $46.4 million $78.8 million (41.1%) Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. ESAB's Business and Current Focus Areas ESAB operates in the global fabrication technology market, supplying products like welding equipment, gas control equipment, consumables, and related automation solutions. Its gas control business serves medical, industrial, and specialty sectors. The company has established a presence in roughly 150 countries, giving it broad geographic reach and exposure to diverse end markets. The business focuses on several key strategies: capturing share in high-growth regions such as India and Asia-Pacific, shifting its sales mix toward gas control and advanced welding equipment, and growing through acquisitions. It also invests heavily in research and development to produce new equipment and improve digital capabilities, and it implements the ESAB Business Excellence (EBX) system for operational improvement. Success factors include maintaining profitability as the portfolio shifts to higher-margin categories, integrating new acquisitions quickly, and managing global supply chains efficiently. Quarter Highlights: Performance, Strategy, and Developments During Q2 2025, ESAB delivered GAAP revenue above expectations, supported mainly by the contribution from newly acquired businesses. On an organic basis—excluding the impacts from acquisitions and currency—revenue declined by 2.2% in Q2 FY2025. This softness was most pronounced in the Americas, where Core sales (non-GAAP) fell 8.7% in Q2 2024. In the Americas, core sales fell 8.7%, with distribution channels showing caution due to tariff uncertainty and other factors. For example, Core sales in the Americas declined from $309.8 million in Q2 2024 to $282.7 million in Q2 2025 (core, excludes Russia), with Adjusted EBITDA (non-GAAP) for the Americas was $56.8 million in Q2 2025. In contrast, EMEA and Asia-Pacific stood out as sources of strength. Core sales in EMEA and APAC climbed 11.0% in Q2 2025, supported by continued robust demand in high-growth markets like India and the Middle East. Core sales in EMEA and APAC rose to $395.7 million in Q2 2025, with Core adjusted EBITDA margin (non-GAAP) expanded to 20.6% in Q2 2025, up from 19.5% in Q2 2024. The company credited both new product uptake and the positive contribution of recent acquisitions for the result. Notably, ESAB completed the purchases of DeltaP and Aktiv, which expand its medical gas control business, and signed an agreement to acquire EWM, a European specialist in heavy industrial and robotic welding equipment. Product innovation continued to be a focus. The company rolled out new welding equipment and gas control solutions, with management reporting 'strong traction' in sales channels. Gas control now represents 18% of total revenue, up from 10% just a few years ago (as stated by management in Q1 2025). Gas control products, which support precise delivery and regulation of gases in medical and industrial environments, are both faster-growing and higher-margin than the company average. Strategic acquisitions in this space, especially in Europe and India, are expected to increase gas control to 25% of total revenue by 2028. Management noted that EBITDA margins in this segment are already ahead of the 2028 target. This drop reflected higher inventory in the Americas, a move to protect the supply chain against possible tariff disruptions. Cash and equivalents (GAAP) totaled $258 million as of Q2 2025. Ongoing acquisition activity and proactive inventory builds did impact cash conversion for the quarter. Looking Ahead: Guidance and Investor Watchpoints Management raised its full-year 2025 outlook. It now expects total core net sales growth of 1.5–3.5% for 2025, with the midpoint of that range above its prior view of (1.0)–1.5%. The projected core adjusted EBITDA range is now $525–$535 million for FY2025, and Core adjusted EPS guidance was raised to $5.15–$5.30 for 2025. These improvements reflect the contribution from acquisitions and some relief from negative currency exchange, but Expectations for core organic growth remain unchanged at 0.0% to 2.0% for the full year 2025. The impact from recent deals—especially DeltaP, Aktiv, and the imminent EWM acquisition—is a key factor in the increased full-year 2025 guidance. Looking ahead, ESAB will need to deliver more tangible organic growth, particularly in the Americas, which continues to experience volume weakness and a cautious channel environment. Management expects negative mid-single-digit core volume growth in the Americas for FY2025. Investors should keep an eye on the pace of integration of new acquisitions and the progress of the gas control segment as it moves toward its 2028 target. Any prolonged softness in free cash flow, persistent tariff uncertainty in North America, or shortfalls in organic growth could become areas of concern. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
33 minutes ago
- Globe and Mail
Townsquare (TSQ) Q2 Revenue Slips 2%
Key Points GAAP revenue edged past analyst estimates at $115.4 million in Q2 2025, though Net revenue (GAAP) declined 2.3% year-over-year. Digital net revenue became a clear majority, while digital growth slowed to 2.1% in Q2 2025, down from stronger recent quarters. Adjusted (Non-GAAP) EPS missed expectations, coming in at $0.22 versus the $0.26 analyst estimate. These 10 stocks could mint the next wave of millionaires › Townsquare Media (NYSE:TSQ), a local media and digital marketing company focused on mid-sized markets, released its second quarter 2025 earnings on August 6, 2025. The company's most notable news: GAAP revenue modestly exceeded Wall Street expectations, reaching $115.4 million compared to the $114.8 million consensus in Q2 2025. Adjusted earnings per diluted share (EPS, Non-GAAP) missed expectations at $0.22, below the $0.26 analyst estimate for Q2 2025. Net income (GAAP) swung strongly positive, moving from a loss in the prior-year period to a $2.0 million gain in Q2 2025—as Digital business accounted for approximately 52% of company revenue and 50% of segment profit in the first half of 2025. The overall quarter showed ongoing digital transformation, resilient profitability, and progress on leverage reduction, but also signs of slower digital growth, as Townsquare's total digital net revenue growth decelerated from +6.4% year-over-year in Q1 2025 to +4.1% for the first six months of 2025 and continued declines in legacy broadcast revenue, with broadcast advertising net revenue decreasing 9.2% year-over-year in Q2 2025 and for the first half of 2025. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS – Diluted (Non-GAAP) $0.22 $0.26 $0.14 57.1 % Revenue (GAAP) $115.4 million $114.8 million $118.2 million (2.3 %) Adjusted EBITDA (Non-GAAP) $26.4 million $26.2 million 0.8 % Net Income (GAAP) $2.0 million $(48.9 million) n/m Digital Net Revenue $61.3 million $60.0 million 2.2 % Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Profile and Key Strategic Areas Townsquare Media operates as a local media, digital marketing, and radio company, but its strategy has increasingly focused on digital products. It serves markets outside the top 50 largest U.S. cities, providing localized digital content, digital advertising, subscription marketing solutions, and broadcasting. The company positions itself as a 'digital first' business, prioritizing growth in digital advertising (the Ignite platform) and subscription marketing solutions (Townsquare Interactive). Recently, the company has worked to shift its revenue mix, moving digital services ahead of traditional broadcast radio. Success now relies on growing digital revenue, maintaining high engagement with local audiences, and leveraging its advantage in markets with fewer large competitors. The company's competitive position outside major media markets and its focus on local content remain central differentiators. Adhering to Federal Communications Commission (FCC) rules and diversifying revenue across business lines are also vital to operations and stability. Quarter in Review: Notable Developments and Segment Trends Digital net revenue grew 2.1% in Q2 2025, now representing 55% of company-wide net revenue in the first half of 2025. While this marked a slowdown versus recent quarters, the digital share both in revenue and profit underscores the strategic shift that is underway. Digital advertising revenue from the Ignite platform rose 2.4% year-over-year in Q2 2025, down from the 8% pace seen in Q1 2025. Subscription digital marketing solutions, delivered through Townsquare Interactive, registered revenue growth of 1.4% in Q2 2025, alongside a pronounced 15.2% jump in segment profit in Q2 2025. Digital segment profit increased 4.3% year-over-year in Q2 2025, with digital-related activities accounted for 56% of segment profit in the first half of 2025. Digital segment margins stood at 27% in the first half of 2025. However, within digital advertising, profit edged down 1.0% in Q2 2025. These results followed a brief dip in customer demand in April 2025, which management linked to heightened economic uncertainty, which rebounded by the latter half of the quarter. Townsquare Interactive's profitability increased sharply in Q1 2025, attributed to efficiencies and operational changes implemented over the past year. The company's legacy broadcast advertising continued to face headwinds. Broadcast ad revenue fell 9.2% in Q2 2025, with segment profit down 8.4% for broadcast advertising in Q2 2025. Management continues to see radio as a cash-generating—if shrinking—business. The focus outside the top 50 markets appears to help dampen some revenue declines as the company takes share in less contested spaces. Other revenue, such as from live events, surged 19.9% in Q2 2025 (GAAP), representing the fastest growth, but remaining a small share of total sales at roughly $5.5 million in Q2 2025. Progress on capital structure continued in the quarter. Townsquare Media repaid $10 million of debt in Q2 2025 and finished Q2 2025 with $467.1 million in outstanding debt and $3.2 million in cash on hand. Net leverage fell slightly to 4.58 times trailing adjusted EBITDA for the twelve months ended June 30, 2025. It maintained a quarterly dividend of $0.20 per share, consistent with prior quarters. Operating cash flow in the first half of 2025 totaled $10.1 million, slightly lower than a year ago. Capital expenditures for the six months ended June 30, 2025, were $8.3 million. Products and Revenue Breakdown Explained The Ignite platform is Townsquare's digital advertising business, offering programmatic—automated and data-driven—buying across online channels such as search, display ads, social media, and video for local businesses. About 60% of segment digital ad revenue came from programmatic in Q1 2025. The Subscription Digital Marketing Solutions segment, Townsquare Interactive, provides software services to small and medium-sized businesses—such as website design, management tools, and online marketing through monthly subscription fees. Each of these areas is targeted toward improving local client engagement and advertising reach in mid-sized markets. Digital revenue streams have surpassed both the company's traditional broadcast radio advertising and smaller 'other' categories, including local events. In Q1 2025, digital advertising comprised 37.3% of net revenue. Subscription digital marketing made up approximately 16% of net revenue in Q2 2025. Broadcast advertising represented 46.3% of total net revenue for the year ended December 31, 2024, and other lines contributed about 5 %. Looking Ahead: Guidance and Key Watch Areas For Q3 2025, management guided to net revenue of $106.5 million to $108.5 million and Adjusted EBITDA is expected to be between $22.0 million and $23.0 million for Q3 2025. For FY2025, Townsquare Media affirmed its outlook, targeting net revenue of $435 million to $440 million and adjusted EBITDA in the $90 million to $94 million range. Both sets of numbers match or slightly narrow the company's prior guidance for Q2 2025 and the full year, indicating management's measured confidence in current trends and spending patterns. Investors will want to monitor the speed of digital growth, which slowed in Q2 2025 after several periods of faster expansion. The shift could be due to maturation, strong prior-year results, or broader uncertainty in economic conditions affecting advertisers. Additionally, the company's cash balance and ongoing leverage will bear watching, especially as dividend payments continue and if advertising demand fluctuates. Townsquare Media continues to pay a quarterly dividend of $0.20 per share. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. *Stock Advisor returns as of August 4, 2025
